1
|
Bailleux C, Zwarthoed C, Evesque L, Baron D, Scouarnec C, Benezery K, Chardin D, Jaraudias C, Chateau Y, Gal J, François E. Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: A prospective study. Radiother Oncol 2023; 188:109905. [PMID: 37678620 DOI: 10.1016/j.radonc.2023.109905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 08/12/2023] [Accepted: 09/01/2023] [Indexed: 09/09/2023]
Abstract
BACKGROUND AND PURPOSE The aim of our prospective study was to assess the prognostic value of 18F-FDG PET/CT performed two months post treatment for anal canal neoplasm. POPULATION AND METHODS Consecutive patients with histologically proved anal cancer, with 18F-FDG PET/CT pre and two months post treatment were included. Patients were not previously treated for this neoplasm and then received radiotherapy ± chemotherapy. Clinical and pathologic data were collected and for 18F-FDG PET/CT visual and quantitative analysis (standardized uptake value, metabolic volume) were performed; response was classified according to EORTC and PERCIST criteria. The results were assessed for disease free survival and local recurrence free survival using the log-Rank test RESULTS: From December 2014 to September 2019, 94 consecutive patients were screened and 78 were included in this study. Median follow-up was 51 months. Two months post treatment, 37 patients (47.4%) had a complete radiological response according to both EORTC and PERCIST criteria, 66 patients (84.6%) had a clinical complete response. For disease free survival, the prognostic value of complete response was statistically significant (p=0.02) with 18F-FDG PET/CT and with clinical examination (p<0.001). For local recurrence free survival, the prognostic value with 18F-FDG PET/CT was lower (p=0.04) than clinical examination (p < 0.007). CONCLUSION While clinical examination remains the gold standard for post treatment evaluation in anal cancer, 18F-FDG PET/CT has a statistically significant prognostic value. These two assessments could be combined to improve early evaluation.
Collapse
Affiliation(s)
- Caroline Bailleux
- Centre Antoine Lacassagne, Department of Medical Oncology, 33 avenue de Valombrose 06189 Nice, France
| | - Colette Zwarthoed
- Centre Antoine Lacassagne, Department of Nuclear Medicine, 33 avenue de Valombrose 06189 Nice, France
| | - Ludovic Evesque
- Centre Antoine Lacassagne, Department of Medical Oncology, 33 avenue de Valombrose 06189 Nice, France
| | - David Baron
- Centre Antoine Lacassagne, Department of Radiation Oncology, 33 avenue de Valombrose 06189 Nice, France
| | - Cyrielle Scouarnec
- Centre Antoine Lacassagne, Department of Radiation Oncology, 33 avenue de Valombrose 06189 Nice, France
| | - Karen Benezery
- Centre Antoine Lacassagne, Department of Radiation Oncology, 33 avenue de Valombrose 06189 Nice, France
| | - David Chardin
- Centre Antoine Lacassagne, Department of Nuclear Medicine, 33 avenue de Valombrose 06189 Nice, France
| | - Claire Jaraudias
- Centre Antoine Lacassagne, Department of Medical Oncology, 33 avenue de Valombrose 06189 Nice, France
| | - Yann Chateau
- Centre Antoine Lacassagne, Department of Medical Statistic, 33 avenue de Valombrose 06189 Nice, France
| | - Jocelyn Gal
- Centre Antoine Lacassagne, Department of Medical Statistic, 33 avenue de Valombrose 06189 Nice, France
| | - Eric François
- Centre Antoine Lacassagne, Department of Medical Oncology, 33 avenue de Valombrose 06189 Nice, France.
| |
Collapse
|
2
|
Bailleux C, Chardin D, Guigonis JM, Ferrero JM, Chateau Y, Humbert O, Pourcher T, Gal J. Survival analysis of patient groups defined by unsupervised machine learning clustering methods based on patient metabolomic data. Comput Struct Biotechnol J 2023; 21:5136-5143. [PMID: 37920813 PMCID: PMC10618114 DOI: 10.1016/j.csbj.2023.10.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 10/16/2023] [Accepted: 10/16/2023] [Indexed: 11/04/2023] Open
Abstract
Purpose Meta-analyses failed to accurately identify patients with non-metastatic breast cancer who are likely to benefit from chemotherapy, and metabolomics could provide new answers. In our previous published work, patients were clustered using five different unsupervised machine learning (ML) methods resulting in the identification of three clusters with distinct clinical and simulated survival data. The objective of this study was to evaluate the survival outcomes, with extended follow-up, using the same 5 different methods of unsupervised machine learning. Experimental design Forty-nine patients, diagnosed between 2013 and 2016, with non-metastatic BC were included retrospectively. Median follow-up was extended to 85.8 months. 449 metabolites were extracted from tumor resection samples by combined Liquid chromatography-mass spectrometry (LC-MS). Survival analyses were reported grouping together Cluster 1 and 2 versus cluster 3. Bootstrap optimization was applied. Results PCA k-means, K-sparse and Spectral clustering were the most effective methods to predict 2-year progression-free survival with bootstrap optimization (PFSb); as bootstrap example, with PCA k-means method, PFSb were 94% for cluster 1&2 versus 82% for cluster 3 (p = 0.01). PCA k-means method performed best, with higher reproducibility (mean HR=2 (95%CI [1.4-2.7]); probability of p ≤ 0.05 85%). Cancer-specific survival (CSS) and overall survival (OS) analyses highlighted a discrepancy between the 5 ML unsupervised methods. Conclusion Our study is a proof-of-principle that it is possible to use unsupervised ML methods on metabolomic data to predict PFS survival outcomes, with the best performance for PCA k-means. A larger population study is needed to draw conclusions from CSS and OS analyses.
Collapse
Affiliation(s)
- Caroline Bailleux
- University Côte d′Azur, Centre Antoine Lacassagne, Medical Oncology Department, Nice F-06189, France
- University Côte d′Azur, Commissariat à l′Energie Atomique et aux énergies alternatives, Institut Frédéric Joliot, Service Hospitalier Frédéric Joliot, laboratory Transporters in Oncology and Radiotherapy in Oncology (TIRO), School of medicine, Nice F-06100, France
| | - David Chardin
- University Côte d′Azur, Commissariat à l′Energie Atomique et aux énergies alternatives, Institut Frédéric Joliot, Service Hospitalier Frédéric Joliot, laboratory Transporters in Oncology and Radiotherapy in Oncology (TIRO), School of medicine, Nice F-06100, France
- University Côte d′Azur, Centre Antoine Lacassagne, Nuclear medicine Department, Nice F-06189, France
| | - Jean-Marie Guigonis
- University Côte d′Azur, Commissariat à l′Energie Atomique et aux énergies alternatives, Institut Frédéric Joliot, Service Hospitalier Frédéric Joliot, laboratory Transporters in Oncology and Radiotherapy in Oncology (TIRO), School of medicine, Nice F-06100, France
| | - Jean-Marc Ferrero
- University Côte d′Azur, Centre Antoine Lacassagne, Medical Oncology Department, Nice F-06189, France
| | - Yann Chateau
- University Côte d′Azur, Centre Antoine Lacassagne, Epidemiology and Biostatistics Department, Nice F-06189, France
| | - Olivier Humbert
- University Côte d′Azur, Commissariat à l′Energie Atomique et aux énergies alternatives, Institut Frédéric Joliot, Service Hospitalier Frédéric Joliot, laboratory Transporters in Oncology and Radiotherapy in Oncology (TIRO), School of medicine, Nice F-06100, France
- University Côte d′Azur, Centre Antoine Lacassagne, Nuclear medicine Department, Nice F-06189, France
| | - Thierry Pourcher
- University Côte d′Azur, Commissariat à l′Energie Atomique et aux énergies alternatives, Institut Frédéric Joliot, Service Hospitalier Frédéric Joliot, laboratory Transporters in Oncology and Radiotherapy in Oncology (TIRO), School of medicine, Nice F-06100, France
| | - Jocelyn Gal
- University Côte d′Azur, Centre Antoine Lacassagne, Epidemiology and Biostatistics Department, Nice F-06189, France
| |
Collapse
|
3
|
Schiappa R, Contu S, Culie D, Chateau Y, Gal J, Pace-Loscos T, Bailleux C, Haudebourg J, Ferrero JM, Barranger E, Chamorey E. Validation of RUBY for Breast Cancer Knowledge Extraction From a Large French Electronic Medical Record System. JCO Clin Cancer Inform 2023; 7:e2200130. [PMID: 37235837 DOI: 10.1200/cci.22.00130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 02/28/2023] [Accepted: 03/24/2023] [Indexed: 05/28/2023] Open
Abstract
PURPOSE RUBY is a tool for extracting clinical data on breast cancer from French medical records on the basis of named entity recognition models combined with keyword extraction and postprocessing rules. Although initial results showed a high precision of the system in extracting clinical information from surgery, pathology, and biopsy reports (≥92.7%) and good precision in extracting data from consultation reports (81.8%), its validation is needed before its use in routine practice. METHODS In this work, we analyzed RUBY's performance compared with the manual entry and we evaluated the generalizability of the approach on different sets of reports collected on a span of 40 years. RESULTS RUBY performed similarly or better than the manual entry for 15 of 27 variables. It showed similar performances when structuring newer reports but failed to extract entities for which changes in terminology appeared. Finally, our tool could automatically structure 15,990 reports in 77 minutes. CONCLUSION RUBY can automate the data entry process of a set of variables and reduce its burden, but a continuous evaluation of the format and structure of the reports and a subsequent update of the system is necessary to ensure its robustness.
Collapse
Affiliation(s)
- Renaud Schiappa
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France
| | - Sara Contu
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France
| | - Dorian Culie
- Cervico-facial Oncology Surgical Department, University Institute of Face and Neck, Nice, France
| | - Yann Chateau
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France
| | - Jocelyn Gal
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France
| | - Tanguy Pace-Loscos
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France
| | - Caroline Bailleux
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - Juliette Haudebourg
- Anatomy and Pathological Cytology Laboratory, Centre Antoine Lacassagne, Nice, France
| | - Jean-Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | | | - Emmanuel Chamorey
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France
| |
Collapse
|
4
|
Schiappa R, Contu S, Culie D, Thamphya B, Chateau Y, Gal J, Bailleux C, Haudebourg J, Ferrero JM, Barranger E, Chamorey E. RUBY: Natural Language Processing of French Electronic Medical Records for Breast Cancer Research. JCO Clin Cancer Inform 2022; 6:e2100199. [PMID: 35960900 PMCID: PMC9470144 DOI: 10.1200/cci.21.00199] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 05/06/2022] [Accepted: 07/08/2022] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Electronic medical records are a valuable source of information about patients' clinical status but are often free-text documents that require laborious manual review to be exploited. Techniques from computer science have been investigated, but the literature has marginally focused on non-English language texts. We developed RUBY, a tool designed in collaboration with IBM-France to automatically structure clinical information from French medical records of patients with breast cancer. MATERIALS AND METHODS RUBY, which exploits state-of-the-art Named Entity Recognition models combined with keyword extraction and postprocessing rules, was applied on clinical texts. We investigated the precision of RUBY in extracting the target information. RESULTS RUBY has an average precision of 92.8% for the Surgery report, 92.7% for the Pathology report, 98.1% for the Biopsy report, and 81.8% for the Consultation report. CONCLUSION These results show that the automatic approach has the potential to effectively extract clinical knowledge from an extensive set of electronic medical records, reducing the manual effort required and saving a significant amount of time. A deeper semantic analysis and further understanding of the context in the text, as well as training on a larger and more recent set of reports, including those containing highly variable entities and the use of ontologies, could further improve the results.
Collapse
Affiliation(s)
- Renaud Schiappa
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Sara Contu
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Dorian Culie
- Cervico-facial Oncology Surgical Department, University Institute of Face and Neck, University of Côte d'Azur, Nice, France
| | - Brice Thamphya
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Yann Chateau
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Jocelyn Gal
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Caroline Bailleux
- Department of Medical Oncology, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Juliette Haudebourg
- Anatomy and Pathological Cytology Laboratory, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Jean-Marc Ferrero
- Anatomy and Pathological Cytology Laboratory, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Emmanuel Barranger
- Department of Medical Oncology, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| | - Emmanuel Chamorey
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, France
| |
Collapse
|
5
|
Gal J, Benidir S, Gilet C, Chateau Y, Schiappa R, Chamorey E, Bozec A, D'andréa G, Fillatre L. Comparaison de différentes méthodes de machine learning supervisé pour l'aide au diagnostic médical des nodules thyroïdiens. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Contu S, Schiappa R, Chateau Y, Chamorey E. Automatisation du processus de réconciliation des événements indésirables graves entre les bases de données d’essais cliniques et celles de pharmacovigilance. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.04.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
7
|
Scheller B, Santini J, Anota A, Poissonnet G, Chateau Y, Schiappa R, Benisvy D, Dassonville O, Bozec A, Chamorey E. [Cross-cultural adaptation of the French version of the thyroid cancer-specific quality of life questionnaire: THYCA-QoL]. Bull Cancer 2021; 108:696-704. [PMID: 33896584 DOI: 10.1016/j.bulcan.2021.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 12/24/2020] [Accepted: 01/04/2021] [Indexed: 11/12/2022]
Abstract
INTRODUCTION The aim of this study was to translate into French the 24 items of the THYCA-QoL questionnaire used in thyroid cancers and then to study its psychometric properties. MATERIALS AND METHODS The THYCA-QoL is a specific questionnaire for evaluating the quality of life of patients undergoing thyroid cancer surgery. It consists of 24 items and is divided into seven dimensions and six isolated questions. The translation has been carried out according to the recommendations of the EORTC. Validation of the translated version was obtained by finding a consensus of experts for each of the items. RESULTS All the original questions of the questionnaire have been adapted into French. The translated questionnaire, named THYCA-CoL-fr, was tested on 60 patients (65 % female), mean age 54.5 years. All questions were well accepted and understood and no missing data were reported. Eight patients (13 %) proposed an item correction to the questionnaire. No attenuation effects (floor or ceiling) were detected. The internal structure was comparable to the original questionnaire: Cronbach α coefficients varied from 0.53 for the oropharyngeal dimension to 0.88 for the voice dimension. The scree-plot highlighted the seven dimensions of the English version. CONCLUSION THYCA-QoL-fr is the first specific French language questionnaire to evaluate the quality of life in thyroid cancer patients undergoing surgery. These first exploratory psychometric results confirmed the conceptual similarity of the French translation and the English version.
Collapse
Affiliation(s)
- Boris Scheller
- Institut universitaire de la Face et du Cou, Université Côté d'Azur, 31, avenue de Valombrose, 06100 Nice, France.
| | - Joseph Santini
- Polyclinique Saint Georges, 2, avenue de Rimiez, 06100 Nice, France
| | - Amélie Anota
- Unité de méthodologie et de qualité de vie en oncologie, CHU Jean Minjoz, boulevard Fleming, 25030 Besançon, France
| | - Gilles Poissonnet
- Institut universitaire de la Face et du Cou, Université Côté d'Azur, 31, avenue de Valombrose, 06100 Nice, France
| | - Y Chateau
- Département de biostatistiques, Centre Antoine-Lacassagne, Université Côté d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - Renaud Schiappa
- Département de biostatistiques, Centre Antoine-Lacassagne, Université Côté d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - Danielle Benisvy
- Pôle d'imagerie médecine nucléaire, Centre Antoine-Lacassagne, Université Côté d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - Olivier Dassonville
- Institut universitaire de la Face et du Cou, Université Côté d'Azur, 31, avenue de Valombrose, 06100 Nice, France
| | - Alexandre Bozec
- Institut universitaire de la Face et du Cou, Université Côté d'Azur, 31, avenue de Valombrose, 06100 Nice, France
| | - Emmanuel Chamorey
- Département de biostatistiques, Centre Antoine-Lacassagne, Université Côté d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| |
Collapse
|
8
|
Gal J, Bailleux C, Chardin D, Pourcher T, Gilhodes J, Jing L, Guigonis JM, Ferrero JM, Milano G, Mograbi B, Brest P, Chateau Y, Humbert O, Chamorey E. Comparison of unsupervised machine-learning methods to identify metabolomic signatures in patients with localized breast cancer. Comput Struct Biotechnol J 2020; 18:1509-1524. [PMID: 32637048 PMCID: PMC7327012 DOI: 10.1016/j.csbj.2020.05.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 05/15/2020] [Accepted: 05/16/2020] [Indexed: 02/08/2023] Open
Abstract
Genomics and transcriptomics have led to the widely-used molecular classification of breast cancer (BC). However, heterogeneous biological behaviors persist within breast cancer subtypes. Metabolomics is a rapidly-expanding field of study dedicated to cellular metabolisms affected by the environment. The aim of this study was to compare metabolomic signatures of BC obtained by 5 different unsupervised machine learning (ML) methods. Fifty-two consecutive patients with BC with an indication for adjuvant chemotherapy between 2013 and 2016 were retrospectively included. We performed metabolomic profiling of tumor resection samples using liquid chromatography-mass spectrometry. Here, four hundred and forty-nine identified metabolites were selected for further analysis. Clusters obtained using 5 unsupervised ML methods (PCA k-means, sparse k-means, spectral clustering, SIMLR and k-sparse) were compared in terms of clinical and biological characteristics. With an optimal partitioning parameter k = 3, the five methods identified three prognosis groups of patients (favorable, intermediate, unfavorable) with different clinical and biological profiles. SIMLR and K-sparse methods were the most effective techniques in terms of clustering. In-silico survival analysis revealed a significant difference for 5-year predicted OS between the 3 clusters. Further pathway analysis using the 449 selected metabolites showed significant differences in amino acid and glucose metabolism between BC histologic subtypes. Our results provide proof-of-concept for the use of unsupervised ML metabolomics enabling stratification and personalized management of BC patients. The design of novel computational methods incorporating ML and bioinformatics techniques should make available tools particularly suited to improving the outcome of cancer treatment and reducing cancer-related mortalities.
Collapse
Affiliation(s)
- Jocelyn Gal
- University Côte d’Azur, Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, Nice F-06189, France
| | - Caroline Bailleux
- University Côte d’Azur, Medical Oncology Department Centre Antoine Lacassagne, Nice F-06189, France
| | - David Chardin
- University Côte d’Azur, Nuclear Medicine Department, Centre Antoine Lacassagne, Nice F-06189, France
- University Côte d’Azur, Commissariat à l’Energie Atomique, Institut de Biosciences et Biotechnologies d'Aix-Marseille, Laboratory Transporters in Imaging and Radiotherapy in Oncology, Faculty of Medicine, Nice F-06100, France
| | - Thierry Pourcher
- University Côte d’Azur, Commissariat à l’Energie Atomique, Institut de Biosciences et Biotechnologies d'Aix-Marseille, Laboratory Transporters in Imaging and Radiotherapy in Oncology, Faculty of Medicine, Nice F-06100, France
| | - Julia Gilhodes
- Department of Biostatistics, Institut Claudius Regaud, IUCT-O Toulouse, France
| | - Lun Jing
- University Côte d’Azur, Commissariat à l’Energie Atomique, Institut de Biosciences et Biotechnologies d'Aix-Marseille, Laboratory Transporters in Imaging and Radiotherapy in Oncology, Faculty of Medicine, Nice F-06100, France
| | - Jean-Marie Guigonis
- University Côte d’Azur, Commissariat à l’Energie Atomique, Institut de Biosciences et Biotechnologies d'Aix-Marseille, Laboratory Transporters in Imaging and Radiotherapy in Oncology, Faculty of Medicine, Nice F-06100, France
| | - Jean-Marc Ferrero
- University Côte d’Azur, Medical Oncology Department Centre Antoine Lacassagne, Nice F-06189, France
| | - Gerard Milano
- University Côte d’Azur, Centre Antoine Lacassagne, Oncopharmacology Unit, Nice F-06189, France
| | - Baharia Mograbi
- University Côte d’Azur, CNRS UMR7284, INSERM U1081, IRCAN TEAM4 Centre Antoine Lacassagne FHU-Oncoage, Nice F-06189, France
| | - Patrick Brest
- University Côte d’Azur, CNRS UMR7284, INSERM U1081, IRCAN TEAM4 Centre Antoine Lacassagne FHU-Oncoage, Nice F-06189, France
| | - Yann Chateau
- University Côte d’Azur, Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, Nice F-06189, France
| | - Olivier Humbert
- University Côte d’Azur, Nuclear Medicine Department, Centre Antoine Lacassagne, Nice F-06189, France
- University Côte d’Azur, Commissariat à l’Energie Atomique, Institut de Biosciences et Biotechnologies d'Aix-Marseille, Laboratory Transporters in Imaging and Radiotherapy in Oncology, Faculty of Medicine, Nice F-06100, France
| | - Emmanuel Chamorey
- University Côte d’Azur, Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, Nice F-06189, France
| |
Collapse
|
9
|
Viotti J, Culie D, Gal J, Schiappa R, Chateau Y, Bozec A, Chamorey E. Comparaison d’une analyse ajustée à une analyse appariée sur un score de propension : application à la survie des carcinomes épidermoïdes de l’oropharynx. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
10
|
Schiappa R, Giroud C, Zorzi K, Chateau Y, Rener D, Barranger E, Chamorey E. PAPY : Pré-screening par Python : une méthode informatique pour détecter les patients éligibles aux études cliniques. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
11
|
Hebert C, Michel C, Sicurani J, Chateau Y, Viotti J, Falewee MN. Analyse longitudinale du support nutritionnel chez des patients primo traités pour un cancer des voies aérodigestives supérieures (VADS) au centre Antoine Lacassagne. NUTR CLIN METAB 2019. [DOI: 10.1016/j.nupar.2019.01.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Bozec A, Schultz P, Gal J, Chamorey E, Chateau Y, Dassonville O, Poissonnet G, Demard F, Peyrade F, Saada E, Benezery K, Leysalle A, Santini L, Messaoudi L, Fakhry N. Evolution and predictive factors of quality of life in patients undergoing oncologic surgery for head and neck cancer: A prospective multicentric study. Surg Oncol 2019; 28:236-242. [PMID: 30851907 DOI: 10.1016/j.suronc.2019.01.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 01/07/2019] [Accepted: 01/27/2019] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The purposes of this study were to assess the evolution of quality of life (QoL) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing oncologic surgery and to determine the predictive factors of post-therapeutic QoL. METHODS All HNSCC patients who underwent primary surgery, between 2012 and 2014, were enrolled in this prospective multicentric study. Patients completed the EORTC QLQ-C30 and QLQ-H&N35 questionnaires before surgery and at 6 months after treatment. Predictive factors of post-therapeutic QoL scores were determined. RESULTS A total of 200 patients were included in this study. There was no significant deterioration of global QoL and no significant increase in general symptoms between the pre- and post-therapeutic periods, but a significant deterioration in role and social functioning, and an increase of most head and neck symptoms. Tumor stage, tumor site and treatment modalities (type of surgery, adjuvant therapy) were the main predictors of QoL scores. We found a negative correlation between satisfaction with the information received and global QoL score or several functioning scales. CONCLUSION HNSCC surgical treatment affects patients QoL mainly by increasing head and neck symptoms, which results in social and role functioning deterioration. These results are of great interest to improve multidisciplinary care of HNSCC patients.
Collapse
Affiliation(s)
| | - Philippe Schultz
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Strasbourg, France
| | - Jocelyn Gal
- Department of Statistics, Centre Antoine Lacassagne, Nice, France
| | | | - Yann Chateau
- Department of Statistics, Centre Antoine Lacassagne, Nice, France
| | | | | | | | - Frédéric Peyrade
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - Esma Saada
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - Karen Benezery
- Department of Radiotherapy, Centre Antoine Lacassagne, Nice, France
| | - Axel Leysalle
- Department of Radiotherapy, Centre Antoine Lacassagne, Nice, France
| | - Laure Santini
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Marseille, France
| | - Lila Messaoudi
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Strasbourg, France
| | - Nicolas Fakhry
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Marseille, France
| |
Collapse
|
13
|
Schiappa R, Chateau Y, Gal J, Daideri G, Lemoine P, Besrest E, Paugam F, François E, Viotti J, Chamorey E. Fouille de données : comment valoriser les ressources de données médicales dans les centres hospitaliers ? Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.03.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
14
|
Gerard JP, Barbet NN, Dejean C, Evesque L, Benezery K, Coquard R, Chateau Y, Gal J, Doyen J, François E. Planned organ preservation for selected T2-3 rectal cancer: French experience using chemoradiotherapy and contact xray boost. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
751 Background: The Lyon R96-02 randomized trial has demonstrated in T2-3 rectal cancer that external beam radiotherapy (EBRT) with Contact X Ray brachytherapy (CXB) boost was increasing clinical complete response, sphincter preservation and in early cases organ preservation. We report French experience in 3 radiotherapy departments using CXB boost with chemoradiotherapy (CRT) in early T2T3N0. Methods: Selection based on digital rectal examination, colonoscopy, MRI (and/or Endorectal-ultrasound). Inclusion : adenocarcinoma (distal, middle rectum), T2 T3a-b, tumor diameter ≤ 4cm, N0, M0. Treatment : CXB (80-110 Gy/3-4 fr) followed by CRT (CAP 50). Tumor response assess on week 14 : DRE, rigid rectoscopy and MRI. Clinical complete response (cCR) defined as no visible tumor, supple rectal wall and TRG 1-2 on MRI. In case of cCR a close surveillance or local excision was proposed. Results: Between 2002 -2016, 84 patients treated. Median age: 75 years, Male: 59, Female: 25. Operable patients: 69 (83%). T2 : 52, T3 : 32 (Lyon Villeurbanne : 16, Macon : 11, Nice : 57). Median follow-up time : 53 months. cCR was achieved in 94% of cases. Local excision performed in 17 patients (ypT0 : 16). At 4 years, the cancer specific survival was 82% [CI:96-70] and the local relapse rate 12% [CI: 2-22]. No isolated perirectal lymph node relapse observed. After 4 years, 3 more local relapses observed (4, 6, 7 years). Main late toxicity ( > 6 months after treatment) was rectal bleeding (radiation telangiectasia) which required plasma argon coagulation in 5 patients. No TME surgery was performed and organ preservation was achieved in all cases. Bowel function was good in 85% of patients (LARS score < 20). Conclusions: When combining CXB with CRT, rectal cancer T2T3a-b N0 ≤4cm achieve a high rate of cCR (≥85%) with organ preservation, good bowel function, low rate of local relapse ( < 15%) and low toxicity. As rectal adenocarcinoma is radioresistant, the treatment must use a CXB boost. Like anal squamous cell cancer, planned organ preservation can be proposed to operable patients. The ongoing European OPERA trial aims at bringing evidence to this option.
Collapse
|
15
|
Gérard JP, Barbet N, Benezery Sanna K, Coquard R, Chateau Y, Gal J, Doyen J. Planned organ preservation for selected T2, T3 rectal cancer: French experience using chemo radiotherapy and contact X ray boost. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Bozec A, Schultz P, Gal J, Chamorey E, Chateau Y, Dassonville O, Poissonnet G, Santini J, Peyrade F, Saada E, Guigay J, Benezery K, Leysalle A, Santini L, Giovanni A, Messaoudi L, Fakhry N. Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study. Eur J Cancer 2016; 67:73-82. [DOI: 10.1016/j.ejca.2016.08.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Revised: 07/15/2016] [Accepted: 08/10/2016] [Indexed: 10/21/2022]
|
17
|
Marcy PY, Dahlet C, Brenet O, Yazbec G, Dubois PY, Salm B, Fouche Y, Mari V, Montastruc M, Lebrec N, Ancel B, Paillocher N, Dupoiron D, Rangeard O, Michel C, Chateau Y, Ettaiche M, Ferrero JM, Chamorey E. [Multicenter validation study of a questionnaire assessing patient satisfaction with and acceptance of totally-implanted central venous access devices]. Bull Cancer 2015; 102:301-15. [PMID: 25799876 DOI: 10.1016/j.bulcan.2015.02.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 01/29/2015] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Most cancer patients require a totally-implanted central venous access device (TIVAD) for their treatment. This was a prospective, multicenter, open study to: (i) develop and validate a French-language questionnaire dubbed QASICC (Questionnaire for Acceptance of and Satisfaction with Implanted Central Venous Catheter) assessing patient's satisfaction with and acceptance of their TIVAD; (ii) develop a mean score of patient's acceptance and satisfaction; (iii) look for correlation between QASICC score and TIVAD patient/tumor pathology/device characteristics. METHODS From 2011 November to 2012 December, the first version of the QASICC questionnaire that included 27 questions assessing seven dimensions was re-tested among 998 cancer patients in eleven French cancer hospitals (eight cancer research institutes and three university/general hospitals). The goal was: (i) to reduce the questionnaire item and dimension number (pertinency, saturation effect, item correlation); (ii) to assess its psychometric properties, demonstrate its validity and independency compared to (EORTC) QLQC30; (iii) to correlate clinical and pathological patient's/tumor's/TIVAD's parameters with the QASICC questionnaire score (the higher the overall score, the greater the acceptance and satisfaction). The questionnaire was administered to the patient 30 days (±15 days) after TIVAD's implantation. RESULTS Among 998 questionnaires given to cancer patients, 658 were analyzed and 464 were fully assessed as there was no missing data. Time to fill-in the questionnaire was five minutes in 90% patients. Final QASICC tool included twenty-two questions assessing four homogeneous dimensions (65%<Cronbach coefficient<85%): (i) impact on daily activities and professional activities; (ii) esthetics and privacy; (iii) pain, contribution to the comfort of the treatment; (iv) local discomfort. Respective assessment scores were 23.6%, 32.9%, 20.4% and 18.0%. Overall satisfaction score was 75.8%; global assessment score was 76.2%. These scores were significantly linked to patient's gender, anesthesia type, TIVAD's implantation side, patient's age and tumor type. CONCLUSIONS This second and final methodological and statistical validation of this auto-questionnaire QASICC allows us to propose it as a dedicated questionnaire to TIVAD's cancer patients by using a score assessing acceptance and satisfaction regarding their device.
Collapse
Affiliation(s)
- Pierre Yves Marcy
- Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 1, France.
| | - Christian Dahlet
- Centre Paul-Strauss, 03, rue de la Porte de l'Hôpital, 67065 Strasbourg cedex, France
| | - Olivier Brenet
- Centre Paul-Papin, ICO, 2, rue Moll, 49933 Angers cedex 9, France
| | - Gabriel Yazbec
- Institut Jean-Godinot, 01, avenue du Général-Koenig, BP171, 51056 Reims cedex, France
| | - Pierre Yves Dubois
- Institut Jean-Godinot, 01, avenue du Général-Koenig, BP171, 51056 Reims cedex, France
| | - Bernard Salm
- Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | - Yves Fouche
- Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 1, France
| | - Veronique Mari
- Hôpital de Jour, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 1, France
| | - Marion Montastruc
- Institut Claudius-Rigaud, 20-24, rue du Pont-Saint-Pierre, 31052 Toulouse cedex, France
| | - Nathalie Lebrec
- Centre Paul-Papin, ICO, 2, rue Moll, 49933 Angers cedex 9, France
| | - Benoit Ancel
- Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | | | - Denis Dupoiron
- Centre Paul-Papin, ICO, 2, rue Moll, 49933 Angers cedex 9, France
| | - Olivier Rangeard
- Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | - Cécile Michel
- Unité de recherche clinique, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Yann Chateau
- Unité d'épidémiologie et de biostatistiques, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Marc Ettaiche
- Unité d'épidémiologie et de biostatistiques, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Jean-Marc Ferrero
- Unité de recherche clinique, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Emmanuel Chamorey
- Unité d'épidémiologie et de biostatistiques, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| |
Collapse
|
18
|
Etienne-Grimaldi MC, François E, Renée N, Cardot JM, Douillard JY, Gamelin E, Chateau Y, Clouet J, Dupuis S, Milano G. Pharmacokinetic (PK) and tolerance profiles of oral tegafur/uracil (UFT) given as three versus two daily intakes. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.12013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12013 Background: This phase II randomized bioequivalence cross-over study compared the tolerance and PK profiles of oral UFT (tegafur-uracil) given as 3 daily intakes (tid, usual schedule) to that obtained with 2 daily intakes (bid). Methods: Twenty-one metastatic colorectal cancer patients were enrolled (16 men, 5 women ; mean age 64, extremes 42–79 ; ECOG PS ≤ 1). Tegafur-uracil (300 mg/m2/d) and leucovorin (90 mg/d) were given for 2 consecutive four-week cycles separated by one rest week. Patients were randomized for receiving 1st cycle either tid (arm A, 12 patients) or bid (arm B, 9 patients). For each schedule, PK was evaluated at steady state, over 24 h. Plasma concentrations of tegafur, uracil and fluorouracil (FU) were analyzed by HPLC. Results: Analysis of tolerance (digestive toxicity mainly, OMS grade) showed a tendency (p = 0.08) for a greater toxicity with the bid schedule (29% grade 2, 14% grade 3) relative to tid (24% grade 2 only). Although daily doses were similar, FU and uracil AUC0–24h were respectively 1.8 and 2.0-fold higher for bid as compared to tid (95% CI were 1.5–2.1 and 1.6–2.6, respectively, p < 0.0001). For tegafur, the 1.2-fold difference was of borderline significance (p = 0.057). The greater the FU AUC0–24h, the higher the toxicity intensity (p = 0.044). Analysis of systemic exposure with respect to daily time revealed that FU (p < 0.01) and uracil (p < 0.03) AUC corresponding to the morning intake were significantly higher than those corresponding to the afternoon or evening intakes, with AUC ratio as high as 1.6 for FU and 2.9 for uracil. Such a circadian influence was not observed for tegafur. Conclusions: To reach bioequivalence, bid tegafur-uracil administration will require lower doses than those given tid. The circadian variability observed for FU and uracil PK concords with that previously reported for dihydropyrimidine deshydrogenase activity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. C. Etienne-Grimaldi
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - E. François
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - N. Renée
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - J. M. Cardot
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - J. Y. Douillard
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - E. Gamelin
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - Y. Chateau
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - J. Clouet
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - S. Dupuis
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| | - G. Milano
- Centre Antoine-Lacassagne, Nice, France; Faculté de Pharmacie, Clermont-Ferrand, France; Centre René Gauducheau, Nantes, France; Centre Paul Papin, Angers, France
| |
Collapse
|